Tag: research

FDA-registered manufacturer examines growing use of high-concentration niacinamide formulas and reports that ingredient balance may play a greater role in product performance than active percentage alone.

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.

New Educational Resource Explains Product Evaluation Factors, Common Buying Mistakes, Verification Trends, and What Consumers Should Review Before Purchase

 ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate production